The Pentagon temporarily rescinds recently published clinical guidance for mandatory testosterone-deficiency screening for some U.S. service members, according to multiple reports citing a U.S. official and Reuters. The guidance was posted on the Pentagon’s website this week and removed the next day, with a message indicating it is being rescinded to allow updates. Interim guidance remains in effect, while the document’s online versions no longer appear.
The withdrawn guidance, titled “Clinical Guidance for Health and Human Performance Optimization,” would have directed testosterone-deficiency screening as part of annual health assessments, targeting personnel aged 30 and older. Several outlets note that the document included separate screening pathways for men and women, with women being assessed for hormonal dysregulation. Forbes and other outlets characterize the rescission as temporary and “for now,” reflecting that the Pentagon’s stated intent is to refine the policy rather than permanently abandon the approach.
Across coverage, the main difference is emphasis: Forbes highlights the implications for women’s screening; other outlets focus on the Pentagon’s decision to rescind the newly posted policy and the timing of its removal and replacement with interim direction.
